@jcancom Hopefully, there will be a combo trial (with an anti-PD-1) in patients with liver mets as they correlate with reduced immunotherapy efficacy ...
@j Checkpoint blockade works in tumours types with mismatch DNA repair defects/p> However, most patients don't have such defects. So, one group ...
Trials (PhI/II) are now recruiting in both South Korea and the US (for patients with HCC), testing oral, IT, or a combo of both/p>
Preclinical data at AACR (the conference is next month) Activity of 3 Bromopyruvate in human tumor primary culture 3-dimensional explants using ...
Faeth Therapeutics is trying to exploit the differences in metabolism and nutrient uptake between healthy and cancerous cells by using a machine learn...
Dr. Yamamoto successfully sold his patents and related IP to Efranat, in late '09, who listing him as a ''co-founder'' (and inventor of GcMAF)/span> ...
@abidingtoday What Joe Tippens seems to have left out was that he took part in a clinical trial (testing Keytruda* +/- other approved drugs), while al...
@abidingtoday This could work/p> Also, some trials are discussed here (starting on page five)/p>
Vitamin C and Cancer: Is There A Use For Oral Vitamin C?/p> I haven't read that in full, but do know from this, ''However, it has been assumed t...
Preclinical data on a fasting mimicking diet/p>
@abidingtoday There are a number of ways THC/CBD can cause immunosuppressionhttps://www.sciencedirect.com/science/article/abs/pii/S0171298509000709/p>...
@abidingtoday I would be cautious about using cannabis with immunotherapy/p>
@j Lilly said it would price sintilimab similar to deeper discounted biosimilars, so about 40% off the wholesale acquisition cost, with the deci...
@jcancom I know another company is running a PhI/II testing a metabolic inhibitor (GAPDH, a-KGDH and NF-kB) in metastatic pancreatic, with stan...
@j Yes, and given for up to two years. I know Eli Lilly (and its partner, Innovent), wanted to disrupt the US anti-PD-1 market with sintilimab (star...
One company is working on first-in-class small molecules and this year should file an IND for its lead program which is a dual MCT1 and MCT4 inhibitor...
Turnstone Bio has struck a research collaboration with the Moffitt Cancer Center. It will support the progress of TIDAL-01 and other TIL candidates. M...
Yes, Cage Pharma wants to move forward with the microencapsulated formulation (given systemically). Hopefully, they will be able to do this, but I rem...
So a dose escalation to find the recommended phase 2 dose, followed by dose expansion cohort(s) of patients. Depending on the data and interactions wi...
@jcancom One company is seeking investment to move it into the clinic/p>
SSRI (selective serotonin reuptake inhibitors) antidepressants slowed the growth of pancreatic and colon cancers in mice, and when combined with a cer...
Replimune have provided an update. For the CERPASS trial (RP1 plus libtayo in advanced cutaneous squamous cell carcinoma), at current data cutoff (n=1...
Another company (Turnstone Bio) plans to test a neoantigen-reactive TIL therapy, then take forward an enhanced version (ex vivo expansion), and will c...
The company using the double positive (CD39+CD103+) TIL population should open a PhI trial in Q3. They are also working with another to 'silence' PD-1...
For PACT Pharma, the combo trial with an anti-PD-1 (up to six doses of Opdivo) should start to enrol patients early next year. NeoTCR-P201 and P211 ar...